These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 25096066

  • 1. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F, Alunno A, Cipriani P, Bartoloni E, Ciccia F, Triolo G, Gerli R, Giacomelli R.
    Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R172. PubMed ID: 24286296
    [Abstract] [Full Text] [Related]

  • 3. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.
    Ann Rheum Dis; 2012 Nov 30; 71(11):1881-7. PubMed ID: 22615459
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD20 antibody in primary Sjögren's syndrome management.
    Chen S, Liu Y, Shi G.
    Curr Pharm Biotechnol; 2014 Nov 30; 15(6):535-41. PubMed ID: 25213362
    [Abstract] [Full Text] [Related]

  • 5. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X.
    Ann Rheum Dis; 2007 Mar 30; 66(3):351-7. PubMed ID: 16950808
    [Abstract] [Full Text] [Related]

  • 6. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A.
    Autoimmun Rev; 2010 Jul 30; 9(9):609-14. PubMed ID: 20452466
    [Abstract] [Full Text] [Related]

  • 7. Biologic treatments in Sjögren's syndrome.
    Bowman S, Barone F.
    Presse Med; 2012 Sep 30; 41(9 Pt 2):e495-509. PubMed ID: 22836195
    [Abstract] [Full Text] [Related]

  • 8. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
    St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P, Autoimmunity Centers of Excellence.
    Arthritis Rheum; 2013 Apr 30; 65(4):1097-106. PubMed ID: 23334994
    [Abstract] [Full Text] [Related]

  • 9. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
    Pollard RP, Abdulahad WH, Bootsma H, Meiners PM, Spijkervet FK, Huitema MG, Burgerhof JG, Vissink A, Kroese FG.
    Ann Rheum Dis; 2013 Dec 30; 72(12):2048-50. PubMed ID: 23864239
    [No Abstract] [Full Text] [Related]

  • 10. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T.
    Am J Gastroenterol; 2012 Aug 30; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract] [Full Text] [Related]

  • 11. Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A, James JA.
    Semin Arthritis Rheum; 2008 Apr 30; 37(5):273-92. PubMed ID: 17714766
    [Abstract] [Full Text] [Related]

  • 12. Present and novel biologic drugs in primary Sjögren's syndrome.
    Fasano S, Isenberg DA.
    Clin Exp Rheumatol; 2019 Apr 30; 37 Suppl 118(3):167-174. PubMed ID: 31025931
    [Abstract] [Full Text] [Related]

  • 13. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F, Sarzi-Puttini P.
    Reumatismo; 2010 Apr 30; 62(2):87-8. PubMed ID: 20657883
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et Inflammations and the French Society of Rheumatology.
    Ann Rheum Dis; 2013 Jun 30; 72(6):1026-31. PubMed ID: 23264337
    [Abstract] [Full Text] [Related]

  • 15. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK.
    Ann Rheum Dis; 2016 Nov 30; 75(11):1933-1938. PubMed ID: 26757748
    [Abstract] [Full Text] [Related]

  • 16. Biologic therapies in primary Sjögren's syndrome.
    Bowman SJ.
    Curr Pharm Biotechnol; 2012 Aug 30; 13(10):1997-2008. PubMed ID: 22208654
    [Abstract] [Full Text] [Related]

  • 17. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
    Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, Cipriani P, Ferrante A, Cannizzaro A, Giacomelli R, Triolo G.
    Rheumatology (Oxford); 2014 Jul 30; 53(7):1313-20. PubMed ID: 24602921
    [Abstract] [Full Text] [Related]

  • 18. Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.
    Lisi S, Sisto M, D'Amore M, Lofrumento DD.
    Int Immunol; 2015 Apr 30; 27(4):183-94. PubMed ID: 25381666
    [Abstract] [Full Text] [Related]

  • 19. [The efficacy and safety of low-dose rituximab in treatment of primary Sjögren's syndrome with thrombocytopenia].
    Zhou L, Xin XF, Wu HX.
    Zhonghua Nei Ke Za Zhi; 2012 Jan 30; 51(1):37-41. PubMed ID: 22490758
    [Abstract] [Full Text] [Related]

  • 20. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
    Abdulahad WH, Kroese FG, Vissink A, Bootsma H.
    J Autoimmun; 2012 Aug 30; 39(1-2):103-11. PubMed ID: 22341852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.